Press Releases

Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the first patient has been dosed in a Phase 1 clinical trial of JANX007 in subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX007 is a prostate-specific membrane antigen (PSMA) directed T cell

Valent BioSciences LLC, the global biorational products leader in agriculture, public health, and forest health, has announced that the company began selling biostimulant products directly to its U.S. customer base on October 1. The new operating unit was established in February 2022 and it is now fully operational, enabling the organization to serve the entire U.S market. This transition marks a major change in the go-to-market strategy for Valent BioSciences, as the company begins selling b

Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces the dosing of the first patient in China in a Phase 1 study of AC0682, an orally bioavailable chimeric degrader molecule designed to target ER protein with high potency and selectivity. “The initiation of this study marks the first program from our chimeric degrader portfolio to enter the clinic in China, after the initiation of AC068

Illumina Inc., a global leader in DNA sequencing and array-based technologies, today announced a strategic research collaboration with AstraZeneca, a global, science-led biopharmaceutical company, to accelerate drug target discovery by combining their strengths in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise. The collaboration will evaluate whether a combined framework of these technologies can increase the yield and co

Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced further collaboration for their manufacturing partnership to include clinical stage plasmid DNA production to support Ray Therapeutics’ lead optogenetics gene therapy program, RTx-015, in clinical trials for patients with retinitis pigmentosa.

Immune-Onc Therapeutics, Inc., a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced it has entered into a clinical trial collaboration and supply agreement with BeiGene to evaluate Immune-Onc’s first-in-class myeloid checkpoint inhibitors, IO-108 and IO-202, in combination with BeiGene’s anti-PD-1 antibody, tislelizumab, as part of its clinical development programs in China. “We are d

Amgen announced the opening of a new research and development site in San Francisco's Oyster Point, continuing the company's nearly two-decade presence in the region. The new site will constitute the company's second largest research and development facility, which focuses on discovering therapeutics for patients living with cancer, inflammatory disease and cardiometabolic disorders. "For nearly two decades Amgen has been present in the San Francisco Bay Area, a reg

Eurofins Viracor, a leader in infectious disease and immunology testing, today celebrated the opening of its expansive new laboratory in Lenexa, KS. The 110,000 square foot, state-of-the-art facility will be home to 450 employees, comprised of 215 current employees and 235 newly created roles and creates additional capacity to support growth in biopharma and transplant diagnostic testing services. The new facility is part of Eurofins Viracor's continued investment in building ca

Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical and nutraceutical excipients, has announced its plans to take direct compression formulation to the next level with the launch of two new mannitol products at this year’s edition of CPHI. In addition, the company will demonstrate its commitment to unlocking healthier futures with a focus on patient centricity. As a sponsor of this year’s conference program, visitors are invited to join Ro

Eisai Co., Ltd. announced that, as part of the strategic investment towards the realization of its medium-term business plan "EWAY Future & Beyond", it has completed construction of the new injection/research building "Eisai Medicine Innovation Technology Solutions" ("EMITS") at the Kawashima Industrial Park located in Gifu Prefecture, Japan. EMITS will be Eisai's global base for formulation and modality research. In recent years, Eisai's dr